Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoHKSE:03839 +2.39%71 ROA % is 7.52% as of Dec. 2025, which is 39% above its 10-year median of 5.42. GuruFocus rates HKSE:03839 with a GF Score™ of 71/100 and a GF Value™ of HK$4.36 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,009 Drug Manufacturers companies, CPBIO Holding Co ranks better than 69.97% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CPBIO Holding Co's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$265 Mil.
CPBIO Holding Co's average Total Assets over the quarter that ended in Dec. 2025 was HK$3,526 Mil. Therefore, CPBIO Holding Co's annualized ROA % for the quarter that ended in Dec. 2025 was 7.52%.
The historical rank and industry rank for CPBIO Holding Co's ROA % or its related term are showing as below:
HKSE:03839'
s ROA % Range Over the Past 10 Years
Min: -1.86 Med: 5.42 Max: 8.51
Current: 6.59
During the past 12 years, CPBIO Holding Co's highest ROA % was 8.51%. The lowest was -1.86%. And the median was 5.42%.
HKSE:03839's ROA % is ranked better than 69.97% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs HKSE:03839: 6.59
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
CPBIO Holding Co ROA % Related Terms
CPBIO Holding Co ROA % Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's ROA % distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
CPBIO Holding Co (HKSE:03839) has a ROA % of 7.52% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CPBIO Holding Co and its competitors. This is 39% above median its historical median of 5.42. According to the industry distribution chart, CPBIO Holding Co ranks #303 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 30%.
Is CPBIO Holding Co's ROA % too high?
CPBIO Holding Co's current ROA % of 7.52% is 39% above median its 10-year median of 5.42. The Drug Manufacturers industry median ROA % is 2.69. CPBIO Holding Co's value of 7.52% is 179.6% above this industry median. Based on the distribution chart, CPBIO Holding Co ranks #303 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #303 out of 1009 companies for ROA %. This puts CPBIO Holding Co in the upper half of its industry. The industry median ROA % is 2.69. CPBIO Holding Co's value of 7.52% is 179.6% above this benchmark. While the company's 10-year median is 5.42 vs. the industry median of 2.69, CPBIO Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current ROA % of 7.52% is 179.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current ROA % is 7.52%, which is 39% above median its own 10-year median of 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$4.36, compared to a current price of HK$9.20 — trading 110.9% above its estimated fair value. The current ROA % is 7.52%, which is 39% above median its 10-year median of 5.42 and 179.6% above the Drug Manufacturers industry median of 2.69. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current ROA % is 7.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for HKSE:03839:
ROA %: 7.52% (39% above median its 10-year median of 5.42)
GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
Industry Position: 179.6% above the Drug Manufacturers median (#303 of 1009)
No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for HKSE:03839
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03839 has been successfully added to your 
